

BIBLIOGRAFIAS ESPECIALIZADAS: su importancia. . .

Lic. M. de los Angeles Mora Ledezma *

A partir de este número de la Revista Costarricense de Salud Pública, iniciamos la publicación de bibliografías especializadas en diversas disciplinas y temas de la salud.

Para la elaboración de citas bibliográficas utilizaremos un formato similar al del Index Medicus. En este formato se incluye: autor, título del artículo, nombre de la revista, volumen, número, páginas, mes, año y número de referencias.

La publicación de bibliografías especializadas en diferentes tópicos, preparadas por una especialista, pretende mantener aún más actualizados a los profesionales en salud. Con ello se les suministrará información rápida, sistematizada y de último momento, dándoles a conocer las investigaciones más recientes, realizadas a nivel mundial en diferentes campos, las publicaciones referentes a ellas y en cuáles revistas se localizan.

Este nuevo modelo informativo ayudará al personal que labora en el área de la salud, a ahorrarse muchísimo tiempo, dinero y complicaciones, cuando acuda a las diferentes bibliotecas en busca de información, pues tendrá de antemano una magnífica orientación al respecto.

Debe tomarse en cuenta que no todos los profesionales y usuarios de información en salud laboran en las ciudades grandes o en zonas céntricas del país, donde se tiene mayor acceso a los medios automatizados, sino que gran cantidad de esta personas trabajan en zonas rurales, donde no hay esas facilidades. En estos casos, serán de mucho beneficio las bibliografías especializadas contenidas en la Revista Costarricense de Salud Pública, las cuales orientarán sobre temas de interés al acercarse a una biblioteca o buscar información pertinente.

Suministramos, en esta oportunidad, una bibliografía que se refiere al importante y actual tema del COLERA, epidemia que en el último año ha afectado tanto a los hermanos países latinoamericanos y que es una amenaza constante contra Costa Rica.

Bibliografía sobre Colera

1. Adbulkadir, S.A. Cholera and cholera-like diarrhoeal diseases: why the differences in severity? *Medical Hypotheses*. 34(3):278-281. Mar. 1991.

2. Alam, A.N. et al. Serum ferritin and cholera: a prospective study. *Tropical and Geographical Medicine*. 43(1-2):12-16. Jan.-Apr. 1991.
3. Anastassiou, E.D. et al. Cholera toxin promotes the proliferation of anti-mu antibody-prestimulated human B cells. *Cellular Immunology*. 140(1):237-247. Mar. 1992.
4. Anastassiou, E.D. et al. Effects of cholera toxin on human B cells. Cholera toxin induces B cell surface DR expression while it inhibits anti-mu antibody-induced cell proliferation. *Journal of Immunology*. 145(8):2375-2380. Oct. 1990.
5. Aronson, S.M. Surveillance in the time of cholera. *Rhode Island Medical Journal*. 74(10):452-453. Oct. 1991.
6. Bhat, B.V. et al. Neonatal cholera in a hospital born baby (letter). *Indian Journal of Pediatric*. 58(1):149-150. Jan-Feb. 1991.
7. Bromander, A.; Holmgren, J. and Lycke, N. Cholera toxin stimulates IL-1 production and enhances antigen presentation by macrophages in vitro. *Journal of Immunology*. 146(9):2908-2914. May. 1991.
8. Clemens, J.D. et al. Field trial of oral cholera vaccine in Bangladesh: evaluation of anti-bacterial and antitoxic breast-milk immunity in response to ingestion of the vaccines. *Vaccine*. 8(5):463-472. Oct. 1990.
9. Clinical diagnosis and treatment of cholera cases. *Epidemiological Bulletin*. 12(1):14-17. 1991.
10. Czerkinsky, C. Antibody producing cells in peripheral blood and salivary glands after oral cholera vaccination of humans. *Infection and Immunity*. 59(3):996-1001. Mar. 1991.
11. Cholera (news). *World Health Fourm*. 12(2):236-240. 1991.
12. Cholera associated with an international airline flight, 1992. *Morbidity and Mortality Weekly Report*. 41(8):134-135. Feb. 1992.
13. Cholera in Africa. *Weekly Epidemiological Record*. 66(42):305-311. Oct. 1991.

* Licenciada en Bibliotecología y Ciencias de la Información. Profesora de la Universidad de Costa Rica. — Especialista en Bibliografías en Salud.

14. Cholera in the Americas. *Weekly Epidemiological Record*. 67(6):33-39. Feb. 1992.
15. Cholera prevention and control: environmental health measures. *Epidemiological Bulletin*. 12(3):13-14,1991.
16. Cholera situation in the Americas. An update. *Epidemiological Bulletin*. 12(1):1-10,1991.
17. Cholera situation in the Americas. An update. *Epidemiological Bulletin*. 12(2):1-4,1991.
18. DePaola, A et al. Isolation of Latin American epidemic strain of *Vibrio cholerae* 01 from US Gulf Coast (letter). *Lancet*. 339(8793):624. Mar. 1992.
19. Deuss, U. Cholera infection with acute renal failure. *Internist*. 32(2):104-106. Feb. 1991.
20. Elson, C.O. Activation of cholera toxin specific T cells in vitro. *Infection and Immunity*. 58(11):3711-3716. Nov. 1990.
21. Environmental health conditions and cholera vulnerability in Latin America and the Caribbean. *Epidemiological Bulletin*. 12(1):18-20. 1991.
22. Environmental health, prevention and control of cholera. *Epidemiological Bulletin*. 12(1):18-20. 1991.
23. Faruque, S.M. and Albert, J. Genetic relation between *Vibrio cholerae* 01 strains in Ecuador and Bangladesh (letter). *Lancet*. 339(8795): 740-741. Mar. 1992.
24. From the Center for Disease Control. Cholera associated with imported coconut milk. *JAMA*. 267(10):1320-1323. Mar. 1992.
25. Glass, R.I. et al. Cholera in Africa: lessons on transmission and control for Latin America. *Lancet*. 338(8770): 791-795. Sep. 1991.
26. Holmgren, J. and Svennerholm, A.M. Development of oral vaccines against cholera and enterotoxinogenic *Escherichia coli*. *Scandinavian Journal of Infectious Diseases*. (76S):47-55. 1990.
27. Jeanes, C.W. Tropical health and quarantine notes. *Canada Diseases Weekly Report*. 17(28): 142,145-146. Jul. 1991.
28. Katoh, S. et al. Modulation of epidermal growth factor binding to receptor by isoproterenol and cholera toxin in primary cultured hepatocytes. *Research Communications in Chemical Pathology and Pharmacology*. 73(2):145-152. Aug. 1991.
29. Leslie, M.; Forges, N.G. and Breedlove, S.M. Does androgen affect axonal transport of cholera toxin HRP in inspinal motoneurons?. *Neuroscience Letters*. 126(2):199-202. May. 1991.
30. Leslie, M.; and Hslbrohr, J. Historial background of cholera in the Americas. *Epidemiological Bulletin*. 12(1):10-12.1991.
31. Ma, Q. J. et al. B subunit of cholera toxin produced in *Escherichia coli*. *Science in China*. 34(3):274-280. Mar. 1991.
32. Marwick, C. Like attacker probing defenses, cholera threatens US population from elsewhere in this hemosphere (news). *JAMA*. 267(10):1314-1315. Mar. 1992.
33. McCarthy, S.A. et al. Toxigenic *Vibrio cholerae* 01 and cargo ships entering Gulf of Mexico (letter). *Lancet*. 339(8793):624-625. Mar. 1992.
34. Mckenzie, F.R. and Milligan, G. Cholera toxin impairment of opioid mediated inhibition of adenylate cyclase in neuroblastoma x glioma hibrid cells is due to a toxin induced decrease in opioid receptor levels. *Biochemical Journal*. 275(part 1):175-182. Apr. 1991.
35. Mokhbat, J.E. Cholera: an ancient disease in modern times (editorial). *Journal Medical Libanais*. 39(1): 1-2.1991.
36. Moren, A. et al. Practical field epidemiology to investigate a cholera outbreak in a Mozambican refugee camp in Malawi, 1988. *Journal of Tropical Medicine*. 94(1):1-7. Feb. 1991.
37. Moscovitchlopatin, M. et al. Interleukin 2-counteracts the inhibition of cytotoxic lymphocytes T by cholera toxin in vitro. *European Journal of Immunology*. 21(6):1439-1444. Jun. 1991.
38. Nettleman, M.D. Cholera, travel, and infection control *Infection Control and Hospital Epidemiology*. 12(9):558-562. Sep. 1991
39. O'Loughlin, E.V.; Scott, R.B. and Gall, D.G. Phathophysiology of infectious diarrhea: changes in intestinal structure and function. *Journal of Pediatric an Nutrition* 12(1):5-20. Jan. 1991.
40. Prasad, R. et al. Biological and immunological characterization of a cloned cholera toxin like enterotoxin from Salmonella typhimurium. *Microbial Pathogenesis*. 9(5):315-330. Mar. 1991.
41. Prevention and treatment of cholera. *Medical Letter on Drugs and Therapeutics*. 33(857):107-108. Nov. 1991.
42. Rabbani, G.H. et al. Efficacy of a single dose of furazolidone for treatment of cholera in children. *Antimicrobial Agents and Chemotherapy*. 35(9):1864-1867. Sep. 1991.
43. Rai, R.N.; Tripathi, V.C. and Joshi, R.D. Persistence of *Vibrio cholerae* in inter epidemic period: preliminary observations on analysis of water. *Journal of Communicable Diseases*. 23(1):44-45. Mar. 1991.
44. Risk of cholera transmission by foods. *Bulletin of the Pan American Health Organization*. 25(3):274-277.1991.

45. Rodman, D.M. and Zamudio, S. The cystic fibrosis heterozygote: advantage in surviving cholera? *Medical Hypotheses*. 36(3):253-258. Nov. 1991.
46. Rumenaph, T. et al. Structural proteins of hog cholera virus expressed by vaccinia virus further characterization and induction of protective immunity. *Journal of Virology*. 65(2):589-599. Feb. 1991.
47. Siddique, A.K. et al. Survival of classic cholera in Bangladesh. *Lancet*. 337 (8750): 1125-1127. May. 1991.
48. Sixma, T.K. Crystal structure of a cholera toxin related heat labile enterotoxin from *E. coli*. *Nature*. 351(6324):371-277. May. 1991.
49. Snow, J. On the mode of communication of cholera 1855. (classical article). *Salud Pública de México*. 33(2):194-201. Mar.-Apr. 1991.
50. Sommermeyer, H. et al. Cholera toxin mediate inhibition of signalling in jurkat complex. *Immunology*. 182(3-4):226-267. Jun. 1991.
51. Swerdlow, D.L. and Ries, A.A. Cholera in the Americas. Guidelines for the clinician. *JAMA*. 267(11):1495-1499. Mar. 1992. (42 refs).
52. Takeda, T. et al. Detection of heat stable enterotoxin in a cholera toxin gene positive strain of *Vibrio cholerae* 01. *Fems Microbiology Letters*. 80(01):23-28. May. 1991.
53. Tamplin, M.L. and Carrillo Parodi, C. Environmental spread of *Vibrio cholerae* in Peru (letter. *Lancet*. 338(8776):1216-1267. Nov. 1991.
54. TDH report updates diagnosing, treating cholera. *Texas Medicine*. 87(11):61-63. Nov. 1991.
55. Tauxa, R.V. and Blake, P.A. Epidemic cholera in Latin America. *JAMA*. 267(10):1388-1390. Mar. 1992. (29 refs).
56. Toda, M. The protective activity of tea against infection by *Vibrio cholerae* 01. *Journal of Applied Bacteriology*. 70(2):109-112. Feb. 1991.
57. Update: cholera outbreak Peru, Ecuador, and Colombia. *Mortality Weekly Report*. 40(13):225-227. Apr. 1991.
58. Update: cholera-Western Hemisphere, 1991. *Morbidity and Mortality Weekly Report*. 40(49):860. Dec. 1991.
59. Update: the cholera situation in the Americas. *Epidemiological Bulletin*. 12(3):11-12.1991.
60. Van Loon, F.P. et al. Low gastric acid as a risk factor cholera transmission application of a new non invasive gastric acid field test. *Journal of Clinical Epidemiology*. 43(12):1361-1367.1990.
61. Walker, M.W. et al. GTP but not GDP analogues promote association of ADP-ribosylation factors, 20-kDa protein activators of cholera toxin, with phospholipids and PC 12 cell membranes. *Journal of Biological Chemistry*. 267(5):2330-3235. Feb. 1992.
62. Young, C.C.; Chuang, Y.C. and Yound, C.D. Non-0:1 *Vibrio cholerae* bacteremia: report of two cases. *Kanseshogaku Zasshi*. 65(11):1479-1483. Nov. 1991. (20 refs).
63. Winner, L. et al. New model for analysis of mucosal immunity: intestinal secretion of specific monoclonal immunoglobulin A from hybridoma tumors protects against *Vibrio cholerae* infection. *Infection and Immunity*. 59(3):977-982. Mar. 1991.